News | April 29, 2025
Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
Strengthening capabilities in Peptide Therapeutics and CDMO services
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Subscribe To Our Newsletter & Stay Updated
